99mTc-MIBI SPECT/CT in Breast Malignancy
Tc-99m Sestamibi SPECT/CT for Prediction of the Response of Locally Advanced Breast Malignancy to Neoadjuvant Chemotherapy
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Terminated
4 patients have been enrolled into the pilot study. No complications reported. Another clinical trial has been designed.
Other terminated trials from London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Other Breast Cancer trials with similar outcome
A NA clinical study on Breast Cancer, this trial is terminated or withdrawn. The trial is conducted by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's and has accumulated 11 data snapshots since 2008. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Apr 2025 — Present [monthly]
Terminated NA
-
Jan 2025 — Apr 2025 [monthly]
Terminated NA
-
Sep 2024 — Jan 2025 [monthly]
Terminated NA
-
Jul 2024 — Sep 2024 [monthly]
Terminated NA
-
Dec 2021 — Jul 2024 [monthly]
Terminated NA
▶ Show 6 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Terminated NA
-
Nov 2020 — Jan 2021 [monthly]
Terminated NA
-
Jun 2018 — Nov 2020 [monthly]
Terminated NA
-
May 2018 — Jun 2018 [monthly]
Terminated NA
-
Aug 2017 — May 2018 [monthly]
Terminated NA
-
Jan 2017 — Aug 2017 [monthly]
Terminated NA
First recorded
Sep 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
- University of Western Ontario, Canada
For direct contact, visit the study record on ClinicalTrials.gov .